Thomas Folinsbee
Direktor/Vorstandsmitglied bei CASI PHARMACEUTICALS, INC.
Aktive Positionen von Thomas Folinsbee
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CASI PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 21.03.2023 | - |
Independent Dir/Board Member | 21.03.2023 | - | |
Shanghai Alebund Pharmaceuticals Ltd. | Corporate Officer/Principal | 01.01.2019 | - |
Karriereverlauf von Thomas Folinsbee
Ehemalige bekannte Positionen von Thomas Folinsbee
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Bison Capital Acquisition Corp.
Bison Capital Acquisition Corp. Financial ConglomeratesFinance Bison Capital Acquisition Corp. is currently a blank check company, which primarily engages in the acquisition, and engagement in share exchange, share reconstruction and amalgamation with, contractual control arrangement with, purchasing all or substantially all of the assets of an entity. It also plans on engaging in any other similar business combination with one or more entities. The company is headquartered in Beijing, China. | Direktor/Vorstandsmitglied | 31.05.2017 | 01.01.2019 |
Independent Dir/Board Member | 31.05.2017 | 01.01.2019 | |
3SBIO INC. | Corporate Officer/Principal | 01.01.2009 | 01.01.2019 |
Hisanaga Seisakusho Co. Ltd. | Direktor/Vorstandsmitglied | 01.01.2011 | 01.01.2016 |
SUMT HEAL | Direktor/Vorstandsmitglied | - | - |
Independent Dir/Board Member | - | - | |
XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | Direktor/Vorstandsmitglied | 01.01.2019 | - |
Independent Dir/Board Member | 01.01.2019 | - |
Ausbildung von Thomas Folinsbee
McGill University | Undergraduate Degree |
Statistik
International
China | 5 |
Cayman Islands | 3 |
Kanada | 2 |
Operativ
Director/Board Member | 5 |
Independent Dir/Board Member | 4 |
Corporate Officer/Principal | 2 |
Sektoral
Health Technology | 4 |
Finance | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
3SBIO INC. | Health Technology |
CASI PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Hisanaga Seisakusho Co. Ltd. | |
Bison Capital Acquisition Corp.
Bison Capital Acquisition Corp. Financial ConglomeratesFinance Bison Capital Acquisition Corp. is currently a blank check company, which primarily engages in the acquisition, and engagement in share exchange, share reconstruction and amalgamation with, contractual control arrangement with, purchasing all or substantially all of the assets of an entity. It also plans on engaging in any other similar business combination with one or more entities. The company is headquartered in Beijing, China. | Finance |
Xynomic Pharmaceuticals Holdings, Inc.
Xynomic Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. It engages in licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma and non-Hodgkin's lymphoma. The company was founded by Yinglin Mark Xu on October 7, 2016 and is headquartered in Shanghai, China. | Health Technology |
Summit Healthcare Acquisition Corp.
Summit Healthcare Acquisition Corp. Financial ConglomeratesFinance Summit Healthcare Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The company was founded on December 22, 2020 and is headquartered in Hong Kong. | Finance |
Shanghai Alebund Pharmaceuticals Ltd. |
- Börse
- Insiders
- Thomas Folinsbee
- Erfahrung